11/02/2013 – parmadaily.it
The 2012 edition of the EU Industrial R&D Scoreboard, compiled by the Joint Research Center of the European Commission on 1,000 European companies, places the Chiesi Group at the top of Italian pharmaceutical companies for investments in Research and Development, ninth in the ranking of the largest national groups in each sector and twelfth among European pharmaceutical multinationals.
«The position occupied in the EU Industrial R&D Scoreboard 2012 confirms the value that the Chiesi Group attributes to innovation as an engine of growth even in the current, difficult economic situation - commented Paolo Chiesi, Vice President and Director of Research & Development - Overall, the pharmaceutical sector shows moderate growth in more mature markets, due to the competition from generic products and the transformation that the sector is going through.
In this context, our company is going against the tide, thanks to the ability to generate value through Research & Development activities and the leadership achieved worldwide by products for respiratory diseases, neonatology and cystic fibrosis, a success that is the result of internal research.»
Investments in R&D made by Chiesi Farmaceutici in 2011 exceeded 169 million euro (over 16% of sales, up by 12.7% over the previous year). A significant result if we consider that the average investment in R&D of European companies in all sectors in 2011 stood at 8.9%.
The Chiesi Group
Founded in 1935 in Parma (Italy), the Chiesi Group created in 2011 a turnover of 1,056 million euros, up by 4.1% compared to the previous year. In 2012, total sales are expected to exceed €1,100 million.
The Group, whose main sectors of activity are in the respiratory therapies and specialist medicine areas, currently has a total of 25 subsidiaries worldwide and is present in over 60 countries with its medicines, produced at the plants in Parma, Blois (France) and Santana de Parnaiba (Brazil).
In 2011 investments in R&D reached €169.3 million, equal to 16% of turnover, a level that the company intends to maintain in the coming years. Planned investments in R&D for 2012 should exceed €180 million.
R&D activities in Parma
